Procedural and follow-up clinical outcomes after chronic total occlusion revascularization: Data from an Indian public hospital

Ajit Ananthakrishna Pillai*, Sakthivel Ramasamy, Kabilan S. Jagadheesan, Santhosh Satheesh, Raja J. Selvaraj, Balachander Jayaraman

Department of Cardiology, Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry, 605006, India

A R T I C L E   I N F O

Article history:
Received 2 August 2018
Accepted 25 December 2018
Available online 26 January 2019

Keywords:
Total occlusion
Outcomes
Revascularization
Ejection fraction
Antegrade technique

A B S T R A C T

Background: Chronic total occlusion (CTO) continues to be challenging lesion subset for percutaneous intervention. Last decade has seen tremendous increase in percutaneous coronary intervention (PCI) in this subset owing to improved understanding of the anatomy and enhanced skillset with availability of dedicated hardware. We sought to study the outcomes of CTO PCI in an Indian public hospital.

Methods: This was a single-center non-randomized descriptive follow-up study on CTO PCI. The endpoints were procedural success, immediate, and late adverse cardiovascular events [major adverse cardiac event (MACE)] and change in angina and left ventricular function at follow-up.

Results: A total 389 CTO lesions were treated with a success rate of 87% (339/389). The mean Japanese chronic total occlusion (J-CTO) score was 1.78 ± 0.12 (mean ± standard deviation). Multivariate analysis of different angiographic components of J-CTO score identified tortuosity (p = 0.001), calciﬁcations (p ≤ 0.001), and blunt stump (p = 0.007) as independent predictors of procedural failure. The perioperative mortality was less than 1%, and the non-life threatening complications were about 4%. The MACE rate was signiﬁcantly higher in the procedural failure group (60%) than in the procedural success group (5.3%, p < 0.001). An increase in left ventricular ejection fraction (LVEF) was noted following successful CTO PCI after complete revascularization.

Conclusions: The success rates for CTO PCI in this registry were about 87%. Immediate and long-term clinical outcomes were better with lower MACE (5%) after a successful procedure. A key outcome variable included an increase in LVEF among patients after a successful CTO PCI. The overall peri-procedural complications were about 5.5%, but majority were non-life threatening.

© 2019 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Chronic total occlusion (CTO) of a major epicardial vessel is seen in up to 20% patients undergoing diagnostic angiography and in up to 35% following an episode of acute coronary syndrome. It is one of the most important indication for referral for coronary artery bypass surgery as well. Of late, there are growing data, which indicate that successful treatment of CTOs results in improved symptoms, prolonged life, and improved left ventricular function status. But the attainment of high-end technical skills, sophisticated hardware, and dedicated training sessions with experts in this field have made a huge impact on the success rates of CTO in developed nations. In developing countries such as India, the situations are different. At one end, the country faces coronary artery disease (CAD) epidemic, and about 20% patients with diagnosed CAD shows the presence of CTO in one of the vessels. At the other end, there is signifi cant lag in attaining required technical skills and availing dedicated CTO hardware. We face many challenges in CTO percutaneous coronary intervention (PCI) especially as the procedure demands huge amount of resources in terms of multiple hardware and technical skill set. As there is no public insurance, all patients end up paying from their own, and poor patients face challenges in approaching private centers for treatment because of high treatment expenses owing to extra requirement of consumables. Public hospitals in India thus receive large infl ux of patients for CTO PCI. We planned to study the procedural and clinical outcomes of CTO PCI in the public hospital set up in India assessing various clinical objectives such as incidence of procedural complications and major adverse cardiac
events (MACEs) such as death, myocardial infarction (MI), and target lesion revascularization (TLR). Improvement in left ventricular function is noted following CTO PCI as many patients exhibit viable and hibernating myocardium supplied by the occluded vessel.\textsuperscript{9,20–23} We also looked at improvement in left ventricular function status in patient groups who had successful and failed CTO PCI.

2. Methods

2.1. Objectives

We planned to assess the procedural and clinical outcomes in CTO PCI. We looked at angina relief, freedom from TLR, and changes in left ventricular function among success and failure groups.

2.2. Design and settings

A prospective study of patients undergoing percutaneous coronary angioplasty for totally occluded coronary artery, duration of which is at least 3 months with flow distal to the occlusion, assessed in thrombolysis in myocardial infarction (TIMI) flow grade, is 0 or 1. Any coronary CTO of more than 3 months duration or if duration is unknown but having symptoms suggestive of myocardial ischemia for more than 3 months were subjected to PCI at Department of Cardiology, at a tertiary care public hospital in South India, which caters to a population of approximately 2 million, and it performs on an average 800 PCIs an year. We included all patients with documented or symptomatic ischemia who underwent CTO PCI at the center during the 7-year period from April 2009 to June 2017 with clinical follow-up for improvement of symptoms, left ventricular function, and MACEs such as death, MI, and target vessel revascularization (TVR). The selection of cases for CTO PCI was as per the existing hospital protocol, and patients with left main and triple vessel disease were excluded. The study was conducted after the approval by institutional ethics committee.

2.3. Preprocedural evaluation

Preprocedural evaluation was done to screen for medical comorbidities such as diabetes mellitus, chronic kidney disease, and hematological abnormalities. Left ventricle function status was assessed in terms of ejection fraction (EF) calculated using M-mode measurements or Simpsons method as required in two-dimensional echocardiography. All diabetic individuals were taken care of their blood glucose along with the avoidance of metformin and optimal hydration prior to the procedure, as practiced in our department. A detailed angiographic analysis including length of CTO, presence of side branch at proximal cap, calcification at proximal cap, ambiguous proximal cap, and Japanese CTO score were recorded. Japanese CTO score involved a 5-point scoring system as follows: (1) blunt stump, (2) calcification, (3) within lesion bending >45°, (4) occlusion length ≥20 mm, and (5) prior failed attempt to revascularize the CTO. Scores of 0 indicate easy, 1 indicative of intermediate, and ≥2 indicates difficult CTO for success. Angiographic characteristics as well as procedural outcomes were compared between success and failure groups.

2.4. Procedure

The procedure of PCI was done under standard protocol with certain variations in technical aspects as clinical and lesion characteristics warrant, which were noted and analyzed in the study. Techniques employed were antegrade guide wire escalation approach, antegrade parallel wire, and dissection/re-entry. The conventional approach was antegrade in this series. The indications for retrograde approach included failed antegrade approach to cross the CTO, which included longer and/or calcified CTO with persistent subintimal wire passage despite parallel wire and intra vascular ultrasound (IVUS)-guided true lumen entry techniques. Primary retrograde approach was chosen in cases with ambiguous proximal CTO and/or aorto-ostial CTO. The retrograde approach included direct wire crossing, kissing wire approach, reverse combined antegrade and retrograde technique (CART), and guide liner reverse CART as specified in the literature. The reverse CART procedures were further defined into classical and contemporary types depending upon the connection zone of antegrade and retrograde systems extending out of the CTO body segment and remaining within the CTO body segment, respectively. The procedural details such as fluoroscopy time, amount of contrast used, guide wires selected, techniques incorporated, restoration of coronary blood flow achieved, assessed in TIMI grades, and the nature of stents employed were studied and analyzed. The success and failure of CTO PCI was documented. Technical success was defined as restoration of TIMI flow grade 2 or 3 at the end of the procedure. Procedural success was defined as technical success without in-hospital cardiac events such as death, MI, urgent coronary artery bypass grafting (CABG), or urgent repeat PCI. The reasons for failure such as failure to cross, failure to track the balloon, and failure to dilate were noted and analyzed. The procedural outcome-related end-points examined in both the success and failed groups included the major complications which were grouped into coronary and non-coronary categories. Coronary complications included dissection, thrombosis, vessel wall hematoma, and perforation. Non-coronary complications involved acute pulmonary edema, heart failure, arrhythmias, and access-related vascular complications.

2.5. Discharge evaluation

All patients were observed in postinterventional care unit. A 12-lead electrocardiography was done for all patients immediately after the procedure and before discharge. Routine renal function assay was done for all patients the day before discharge. Postinterventional therapy included dual antiplatelets and other secondary prevention drugs. Vascular access site care was given for all patients.

2.6. Follow-up

All patients who underwent either successful or failed interventions were followed up for 12 months either on outpatient basis or telephonic conversation every 3 months. Thereafter, the follow-up was every 6 months. Patients in either group were evaluated during their follow-up period for occurrence of clinical outcome–related end-points such as freedom or recurrence of angina, improvement in left ventricular function status, and TVR in the form of CABG or repeat PCI. Echocardiography was performed before and after the procedure and at 6 months intervals to record the changes, if any, in the left ventricular ejection fraction (LVEF) which was calculated using M-mode measurements or Simpson’s method as required in two-dimensional echocardiography. While routine check angiography was not planned, patients who developed angina were subjected to coronary angiography with an intention to treat.

2.7. Statistical analysis

Categorical variables are expressed as numbers and percentages, and continuous variables are expressed as the
mean ± standard deviation (SD). After testing for normal distribution, differences were compared using the unpaired Student t-test, chi-square test, Mann–Whitney test, and/or analysis of variance (ANOVA) where appropriate. Univariable and multivariable logistic regression analyses were used to identify predictors of procedural success.

A propensity score was constructed using binary logistic regression where the dependent variable was procedural success, and predictors were clinical and angiographic variables [angiographic variables were adapted from the Japanese chronic total occlusion (J-CTO) score] that are known to be related to clinical outcomes (MACE): age, gender, diabetes mellitus, arterial hypertension, smoking, previous MI, previous PCI, coronary artery, CTO length, presence of calcifications, tortuosity, and stump morphology. The comparison of continuous variables between the procedural outcomes, clinical outcomes and also between the demographic and clinical factors was carried out by using independent Students t-test/Mann–Whitney U test or one-way ANOVA/Kruskal–Wallis test, whichever is appropriate based on the distribution of data and the number of groups. A propensity score-adjusted Cox regression was performed to assess the relation between procedural success and MACE, controlling for group differences.

Event-free survival curves for adverse cardiac events were estimated by Kaplan–Meier method and compared by the log-rank test. A p value less than 0.05 was considered as statistically significant. All statistical analyses were performed with SPSS, version 21.

3. Results

Study population: The study population consisted of 389 patients with chronic total coronary occlusions in whom percutaneous recanalization was performed.

The characteristics of the patients are summarized in Table 1. Based on procedural success, the patients were divided into two groups: a procedural successful group (n = 339/389, 87.8%) and a procedural failure group (n = 50, 12.8%). The mean J-CTO score was 1.78 ± 0.12 (mean ± SD). There were no statistically significant differences in demographic and clinical characteristics between the two groups, except for the higher incidence of a previous MI (p = 0.023) and lower incidence of unstable angina (p < 0.001) in the failure group of patients.

Angiographic characteristics (Table 2): Regarding angiographic characteristics, there were certain differences between the successful and failure groups—lesions longer than 20 mm, more tortuous vessels, and calcifications were all more frequent in the failure group. Procedural success was achieved in 339 lesions (87.8%). Based on these procedural outcomes, the lesions were divided into two groups: a procedural success group (n = 339) and failure group (n = 50). There were no statistically significant differences in procedural characteristics between the two groups. The mean J-CTO score in successful and failed groups were not different. However on analyzing different components of the score, longer CTO length (>20 mm), severe calcification, blunt proximal cap, and tortuosity were more prevalent in the failed group. The peri-procedural complication rate was similar in both groups (Table 3).

### Table 1

Demographics characteristics.

| Characteristic [n (%)] | Total number of lesions (n = 389) | Procedure successful (n = 339) | Procedure failure (n = 50) | p value | OR (95% CI) |
|------------------------|-----------------------------------|-------------------------------|---------------------------|---------|-------------|
| Age (years, mean ± SD) | 58.5 ± 9.5                        | 58.3 ± 9.6                    | 58.8 ± 9.3                | 0.69    | --          |
| Male                   | 318 (81%)                         | 297 (88%)                     | 40 (80%)                  | 0.45    | 0.888 (0.423–1.741) |
| Family history of CAD  | 89 (22%)                          | 47 (14%)                      | 42 (84%)                  | 0.47    | 1.291 (0.733–2.207) |
| Diabetes               | 101 (25.9%)                       | 91 (27%)                      | 10 (20%)                  | 0.19    | 1.347 (0.826–2.264) |
| Insulin dependent      | 14 (3.5%)                         | 11 (4%)                       | 3 (6%)                    | 0.65    | 0.676 (0.262–2.301) |
| Hypertension           | 313 (80.4%)                       | 274 (81%)                     | 39 (79%)                  | 0.70    | 1.233 (0.616–2.046) |
| Hypercholesterolemia   | 313 (78%)                         | 273 (80.8%)                   | 40 (79.2%)                | 0.14    | 1.450 (0.870–2.728) |
| Smoking status         |                                   |                               |                           |         |             |
| Never                  | 159 (41%)                         | 138 (40.7%)                   | 21 (42%)                  | 0.99    | 1.003 (0.614–1.637) |
| Smoker                 | 121 (31.1%)                       | 108 (32%)                     | 13 (26%)                  | 0.30    | 1.226 (0.773–1.927) |
| Ex-smoker              | 110 (28.2%)                       | 94 (28%)                      | 16 (33%)                  | 0.30    | 0.660 (0.451–1.281) |
| Previous MI            | 236 (60.6%)                       | 200 (59%)                     | 36 (72%)                  | 0.02*   | 0.449 (0.326–0.925) |
| LVEF (%)               | 45 ± 13                           | 46 ± 14                       | 44 ± 12                   | 0.188   | --          |
| LVEF < 40%             | 129 (33%)                         | 111 (31%)                     | 18 (37%)                  | 0.281   | 0.857 (0.455–1.525) |
| Previous CABG          | 41 (11%)                          | 36 (12%)                      | 5 (10%)                   | 0.55    | 1.371 (0.574–2.814) |
| Previous PCI           | 260 (67%)                         | 223 (66%)                     | 37 (73%)                  | 0.82    | 0.842 (0.564–1.574) |
| Same artery            | 41 (11%)                          | 36 (12%)                      | 5 (10%)                   | 0.73    | 1.243 (0.528–2.467) |
| Other artery           | 91 (23.3%)                        | 69 (22%)                      | 21 (42%)                  | 0.99    | 1.11 (0.558–1.792) |
| Stable angina pectoris | 151 (38.8%)                       | 121 (58%)                     | 30 (61%)                  | 0.68    | 0.8 (0.550–1.473)  |
| Unstable angina pectoris | 98 (24.8%)                     | 92 (27%)                      | 6 (12%)                   | <0.01*  | 3.508 (1.689–7.285) |
| Number of diseased vessels |                              |                               |                           |         |             |
| 1                      | 178 (46%)                         | 155 (46%)                     | 23 (48%)                  | 0.73    | 0.919 (0.564–1.490) |
| 2                      | 136 (35%)                         | 122 (38%)                     | 16 (33%)                  | 0.72    | 1.096 (0.659–1.823) |
| 3                      | 73 (19%)                          | 62 (19%)                      | 11 (22%)                  | 0.99    | 1.003 (0.543–1.854) |
| Concomitant therapy    |                                  |                               |                           |         |             |
| Beta-blocker           | 241 (62%)                         | 210 (62%)                     | 31 (63%)                  | 0.859   | 1.046 (0.636–1.722) |
| ACE inhibitor and/or ARB|                              |                               |                           |         |             |
| ARB                    | 313 (81%)                         | 271 (80%)                     | 42 (84%)                  | 0.401   | 1.312 (0.695–2.477) |
| Statin                 | 331 (85%)                         | 291 (86%)                     | 40 (81%)                  | 0.266   | 0.694 (0.364–1.324) |
| Nitrate                | 102 (26%)                         | 74 (22%)                      | 28 (27%)                  | 0.363   | 1.296 (0.741–2.268) |
| DAPT                   | 389 (100%)                        | 339 (100%)                    | 50 (100%)                 | --      | --          |

LVEF, left ventricular ejection fraction; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy; OR, odds ratio; CI, confidence interval; SD, standard deviation; MI, myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease; CABG, coronary artery bypass grafting.

*p < 0.05.
The CTO techniques included antegrade approach in 351 patients (90.2%) and retrograde in 38 patients (8.9%) [Tables 2 and 3]. The different antegrade and retrograde techniques that were involved are detailed in Table 3. No statistically significant association was seen between the occluded vessel targeted for intervention and the procedural success (p = 0.13 by chi-square test). The distribution of de novo occlusion and in-stent re-occlusion did not affect the procedural outcome (p = 1.0 by Fishers exact test) as well. Miracle series (37%) and Gaia series (35%) wires were the frequently used for the antegrade approach and SION and Fielder XT series for the retrograde channel crossing (all from ASAHI, Nagoya, Japan). The guide wire details are given in Fig. 1. The mean stent length ± SD was 41.02 ± 19.61 mm. Of 339 lesions which were stented, 244 (72.1%) had single stent, 86 (25.4%) had two overlapping stents, and eight (2.5%) had three stents. The reasons for the procedural failure (n = 50) included failure to cross in 42 patients (84%), failure to track the balloon in two (4%), failure to dilate the balloon in three (6%), and no-reflow in three patients (6%). Figs. 2 and 3 show successful retrograde techniques used for CTO PCI.

By univariate analysis (Table 4), the following factors were identified as predictors of procedural failure: previous MI (p = 0.023), occlusion length > 10 mm (p = 0.037), occlusion length > 20 mm (p = 0.003), presence of tortuosity (p < 0.001), mild calcified lesions (p = 0.012), moderately calcified lesions (p = 0.025), severe calcified lesions (p = 0.001), presence of a side branch at the site of occlusion (p = 0.004), and blunt morphology of the occlusion (p < 0.001). Unstable angina pectoris (p = 0.001) and tapered stump morphology (p = 0.001) were identified as predictors of procedural success. Multivariate analysis of different angiographic components of J-CTO score showed tortuosity (p = 0.001), calcifications (p ≤ 0.001), and blunt stump (p = 0.007), as independent predictors of procedural failure. With regards to clinical variables, a history of unstable angina pectoris was found to be a predictor of procedural success (p = 0.003). Multivariate analysis of different angiographic components of J-CTO score showed tortuosity (p = 0.001), calcifications (p ≤ 0.001), and blunt stump (p = 0.007), as independent predictors of procedural success with regards to clinical variables, a history of unstable angina pectoris was found to be a predictor of procedural success (p = 0.003).

### Table 2

| Angiographic characteristic | No of CTO (n = 389) | Procedure successful (n = 339) | Procedure failure (n = 50) | p value |
|-----------------------------|--------------------|-------------------------------|---------------------------|---------|
| RCA                         | 177 (45.5)         | 152 (45)                      | 25 (51)                   | 0.390   |
| LAD                         | 113 (29)           | 101 (30)                      | 12 (25)                   | 0.393   |
| Cx                          | 92 (24)            | 81 (24)                       | 11 (24)                   | 0.909   |
| Localization of CTO [n (%)] |                    |                               |                           |         |
| Ostial                      | 36 (9)             | 33 (10)                       | 3 (6)                     | 0.139   |
| Proximal                    | 116 (29.1)         | 99 (31)                       | 17 (35)                   | 0.609   |
| Distal                      | 171 (44)           | 149 (44)                      | 22 (44)                   | 0.180   |
| In-stent CTO [n (%)]        | 58 (15)            | 49 (14.5)                     | 9 (16)                    | 0.890   |
| Duration of occlusion [months, mean ± SD] | 36.6 ± 50.0 | 34.4 ± 44.6 | 39.8 ± 56.9 | 0.507   |
| Diameter of CTO vessel [mm, mean ± SD] | 3.0 ± 0.4 | 3.1 ± 0.4 | 3.0 ± 0.4 | 0.273   |
| J-CTO score mean ± SD       | 1.78 ± 0.12        | 1.72 ± 0.17                   | 2.0 ± 0.21                | 0.823   |

### Table 3

| Technique                              | n (%)   |
|----------------------------------------|---------|
| Antegrade wire escalation              | 216 (63.71) |
| Parallel wire technique                | 90 (26.54) |
| Antegrade dissection and re entry      | 18 (5.32)  |
| IVUS-guided proximal cap penetration   | 5 (1.34)  |
| Retrograde wire direct crossing        | 3 (0.88)  |
| Retrograde wire kissing technique      | 5 (1.34)  |
| Reverse CART (classical)              | 19 (5.60) |
| Reverse CART (contemporary)           | 6 (1.96)  |
| Retrograde rendezvous                  | 2 (0.58)  |
| Guide liner reverse CART              | 1 (0.28)  |

IVUS, intravascular ultrasound; CART, controlled antegrade and retrograde tracking; CTO, chronic total occlusion.
Patient succumbed to cardiac arrest. The third patient had sudden death on the first postoperative day in the recovery ward. Coronary perforations were noted in nine (3.1%) patients, and large intramural hematoma with no reflow was documented in 12 (2.01%) patients. Cardiac tamponade occurred in two (1.4%) patients. Vascular complications included retroperitoneal hematoma1 (0.2%), femoral artery thrombosis in two (0.5%), and femoral artery pseudoaneurysm in four (1.02%) patients. Four patients had stent occlusions (1%) in the first year of follow-up.

3.2. Follow-up analysis

The median follow-up period was 63 months (interquartile range: 59–74). The total number of MACE was 48/389 (12.3%), and there were significantly higher adverse events in failure group \((p < 0.001)\) (Table 6). The MACE rate was significantly higher in the failure group (60%) than in success group (5.3%, \(p < 0.001\)). The rate of TVR (both PCI and CABG) was statistically higher in the procedural failure group \((p = 0.009)\). Non-adjusted analysis showed procedural success was found to be a significant predictor of MACE by univariable Cox regression analysis [hazards ratio (HR): 0.423; 95% confidence interval (CI): 0.243–0.739; \(p = 0.002\)]. Propensity score-adjusted Cox regression showed that procedural success remained a significant predictor of MACE [adjusted HR: 0.402; 95% CI: 0.196–0.824; \(p = 0.013\)]. Kaplan–Meier curves showed significantly better survival without MACE in the group of patients with successful treatment of CTO. Average survival-free time from MACE in the procedural success group was 69 ± 2 months and 46 ± 3
months in the failure group (log rank: 15.247, \( p < 0.001 \); HR: 2.7, 95% CI: 1.610–4.163, \( p < 0.001 \)). Although opening a CTO of a target vessel was associated with increased average MACE free time, there was no difference regarding a treated coronary artery (log rank 2.098, \( p = 0.350 \); LAD compared with circumflex artery (LCx) (HR: 2.4, 95% CI: 0.690–8.060, \( p = 0.171 \)); RCA compared with the LCx (HR: 0.796, 95% CI: 0.313–2.021, \( p = 0.631 \)); and LAD compared with the RCA (HR: 1.4, 95% CI: 0.787–2.441, \( p = 0.259 \)). Fig. 4 shows the Kaplan–Meier survival curves with respect to CTO PCI success or failure according to MACE-free survival. It was significantly better without MACE between CTO PCI success and CTO PCI failure in patients with CTO of the left LAD. In LAD patients, average survival free of MACE time in the procedural success group was 59.8 ± 2.4 months and 41.9 ± 6.8 months in the procedural failure group (log rank 14.638, \( p < 0.001 \)). There were no differences between CTO PCI success and CTO PCI failure in patients with CTO of the RCA (log rank 2.850, \( p = 0.091 \)) or LCx (log rank 1.449, \( p = 0.284 \)).

3.3. Left ventricular function

Left ventricular function assessed in terms of EF in percentage (%) improved from 51.66 ± 12.1% at baseline to 54.6 ± 10.34% at 12 months clinical follow-up in patients (n = 339) who met procedural success (increase in the order of 4 ± 5 percentage points).

Whereas, it showed a declining trend from 51.12 ± 9.67% at baseline to 46.5 ± 10.1% at 12 months in patients (n = 50) who met procedural failure (decrease in the order of 4.3 ± 5 percentage points) as shown in Fig. 5.

4. Discussion

This study attempts to look at the procedural and clinical outcomes of CTO PCI in a public hospital set up in a developing nation such as India. Patients with triple vessel disease and left main involvement were excluded. The overall success rate for the CTO was about 87%. This was slightly lower than published series from
Table 4
Univariate analysis of predictors of procedural failure.

| Variable                      | Odds ratio | 95% CI     | p value |
|-------------------------------|------------|------------|---------|
| Male                          | 1.321      | 0.672–2.340| 0.577   |
| Age                           | 0.987      | 0.973–1.023| 0.969   |
| Family history of CAD         | 1.086      | 0.733–1.973| 0.479   |
| Diabetes mellitus             | 1.566      | 0.826–2.462| 0.387   |
| Hypertension                  | 1.121      | 0.616–2.046| 0.706   |
| Hypercholesterolemia          | 1.321      | 0.870–2.728| 0.237   |
| Smoking status                |            |            |         |
| Smoker                        | 1.386      | 0.808–2.340| 0.340   |
| Ex-Smoker                     | 0.689      | 0.435–1.218| 0.326   |
| Previous MI                   | 0.523      | 0.326–0.925| 0.013   |
| LVEF                          | 1.109      | 0.978–1.407| 0.302   |
| Stable angina                 | 0.987      | 0.574–1.516| 0.780   |
| Unstable angina               | 3.342      | 1.600–6.559| 0.001   |
| Previous CABG                 | 1.765      | 0.574–2.614| 0.354   |
| Previous PCI                  |            |            |         |
| Same artery                   | 1.075      | 0.547–2.562| 0.668   |
| Other artery                  | 1.068      | 0.599–1.906| 0.823   |
| No. of diseased vessels       |            |            |         |
| 1                             | 0.980      | 0.577–1.500| 0.767   |
| 2                             | 1.956      | 0.642–1.737| 0.830   |
| 3                             | 1.036      | 0.562–1.911| 0.999   |
| Concomitant therapy           |            |            |         |
| Beta-blocker                  | 0.491      | 0.137–1.763| 0.276   |
| ACE inhibitor and/or ARB       | 1.602      | 0.224–5.024| 0.140   |
| Statin                        | 0.656      | 0.138–3.134| 0.598   |
| Nitrate                       | 0.607      | 0.128–2.880| 0.530   |
| CTO                           |            |            |         |
| RCA                           | 0.774      | 0.481–1.247| 0.293   |
| LAD                           | 1.336      | 0.780–2.298| 0.391   |
| Lcx                           | 1.033      | 0.592–1.802| 0.909   |
| Occlusion duration            | 0.998      | 0.992–1.004| 0.507   |
| CTO vessel diameter           | 0.856      | 0.488–1.500| 0.587   |

Table 5
Periprocedural complications.

| n (%) | Total (389) | Success | Failure | p value |
|-------|-------------|---------|---------|---------|
| Death | 3           | 2       | 1       | 0.9     |
| MI    | 2 (0.7)     | 1 (0.6) | 1 (2)   | 0.597   |
| Coronary perforation           | 7 (1.7)   | 4 (1.0) | 3 (6)   | 0.068   |
| Cardiac tamponade              | 3 (0.7)   | 1 (0.3) | 2 (4)   | 0.719   |
| Vascular complication          | 7 (1.9)   | 5 (1.4) | 2 (4)   | 0.613   |
| Donor vessel dissection        | 2 (0.5)   | 1 (0.4) | 1 (2)   | 0.719   |

MI, myocardial infarction.

We already have data showing improved success rates in complex CTO with hybrid/retrograde approaches.26,27 The mean J-CTO score was 1.7 marginally higher in failed cases (1.7 vs. 2) (p = 0.7), but when individual components of J-CTO score were compared against success and failure and tortuous and calcified CTOs, they showed higher failure rates in the multivariate analysis. CTO PCI improved symptoms, and a successful attempt reduced the MACE as shown in the previous studies.28–30 Developing economies such as India have logistic issues as well in accessibility for dedicated CTO tools for complex retrograde procedures which often have an impact on the outcomes.31-33

The predominant CTO crossing technique was antegrade wire escalation (60%) followed by parallel wire technique (26%) in the antegrade approach, while reverse CART formed the major technique in the retrograde approach (5.6%). We believe the success rate can be even higher with more routine usage of retrograde techniques which could prove crucial in complex CTO success.34 The Japanese multicenter CTO registry showed higher success rates up to 95%.35 The registry has quoted up to 30% retrograde channel approach.36

The periprocedural mortality was less than 1%, and the non-life threatening complications were about 4%. The clinical outcomes were acceptable and durable in this series. We had low MACE (5.3%) after a successful CTO PCI. The TLR rates were also acceptable in the relatively longer follow-up interval compared with previous studies from India by KS and Got and colleagues.37 Although opening a CTO of a target vessel was associated with increased average MACE-free time, there was no difference regarding a treated coronary artery which was similar to previously published literature.38-40

The important finding of the study was the positive impact of successful CTO PCI on left ventricular function. There was an improvement in the LVEF following successful CTO PCI at 6 months of follow-up contrary to the declining trend in the LVEF following failed CTO PCI. This improvement in LVEF was maintained at 24 months. This objective finding with statistical significance attests to the clinical outcome of CTO PCI as shown in earlier studies.32,34 We feel this is an important outcome, as it will stimulate CTO PCI programs in countries where facilities for such resource demanding procedures are not routinely met.

5. Limitations of the study

This study is mainly limited by the fact that it is a single-center non-randomized data. The number of patients was small enough to draw powerful long-term data. The study did not use any qualitative and quantitative intravascular ultrasound assessments, and therefore angiographic predictors of outcome cannot be discerned. Non-invasive stress testing test was not performed to objectively assess angina symptoms and performance. Absence of significant angina (CCS class III/IV; postprandial angina) at follow-up qualified to be considered as symptomatic benefit in our study.
besides taking into account the patients’ symptom status at presentation. Myocardial viability assessment was not done in our study, but we have included only patients with symptom limiting daily activities, which indirectly corroborates for presence of viable myocardium downstream. The absence of a surgical arm of revascularization (CABG) is another limitation of this study.

6. Conclusions

The success rates for CTO PCI in this registry was about 87%. Immediate and long-term clinical outcomes were better with lower MACE (5%) after a successful procedure. A key outcome variable included an increase in LVEF among patients after a successful CTO PCI. The overall periprocedural complications were about 5.5%, but majority were non-life threatening.

Conflicts of interest

All authors have none to declare.

Acknowledgements for funding

None.

References

1. Stone GW, Kandzari DE, Mehran R, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation. 2005 Oct 11;112(15):2364–2372.
2. Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation. 2005 Oct 18;112(16):2530–2537.
3. Kaúl U. Cardiovascular disease epidemics in India—a continuing problem. J Assoc Phys India. 2012 Mar;60:9–15.
4. Dash D. Guidewire crossing techniques in coronary total occlusion intervention: a to Z. Indian Heart J. 2016 May-Jun;68(3):410–420. https://doi.org/10.1016/j.ihj.2016.02.019.
5. Dash D. Retrograde coronary chronic total occlusion intervention using a novel reverse controlled antegrade and retrograde subintimal tracking. J Interv Cardiol. 2016;29:70–74, 2.
6. Ishizaka N, Sisisky T, Saeki F, et al. Angiographic follow-up after successful percutaneous coronary angioplasty for chronic total coronary occlusion: experience in 110 consecutive patients. Am Heart J. 1994 Jan;127(1):8–12.
7. Kinoshita I, Katoh O, Nariyama J, et al. Coronary angioplasty of chronic total occlusions with bridging collateral vessels: immediate and follow-up outcome from a large single-center experience. J Am Coll Cardiol. 1995 Aug;26(2):409–415.
8. Noguchi T, Miyazaki MD, Morii I, Daikoku S, Goto Y, Nonogi H. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Determinants of primary success and long-term clinical outcome. Cathet Cardiovasc Interv. 2000 Mar;49(3):258–264.
9. Olivari Z, Rubartelli P, Piscione F, et al, TOAST-GISE Investigators. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multi centre, prospective, observational study (TOAST-GISE). J Am Coll Cardiol. 2003 May 21;41(10):1672–1678.
10. Ks G, Type M, Viswanathan S, et al. Angiographic predictors of success at antegrade approach of Chronic Total Occlusion interventions in a South Indian population in the contemporary era. Indian Heart J. 2018 Jan-Feb;70(1):15–19.
11. Simons PA, Golf S, Myereg Y, et al. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996 Nov 15;28(6):1444–1451.
12. Violaris AG, Melkert E, Serruys PW. Long-term luminal re-narrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis. Circulation. 1995 Apr 15;91(8):2140–2150.
13. Christakopoulos GE, Tatar MNJ, Brilakis ES. The impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcomes. J Thorac Dis. 2015 Jul;7(7):1107–1110.
14. Hoebers LP, Claessen BE, Elias J, Dangas GD, Mehran R, Henriquez JPS. Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. Int J Cardiol. 2015;187:90–96.
15. Fefer P, Knudson ML, Cheema AN, et al. Current perspectives on coronary chronic total occlusions, the Canadian multicentre chronic total occlusions registry. J Am Coll Cardiol. 2012;59:981–997.
16. Råmunddal T, Hoebers LP, Henriques JP, et al. Chronic total occlusions in Sweden - a report from the Swedish coronary angiography and angioplasty registry (SCAAR). PLoS One. 2014;9:e103850.

17. Opolski MP, C19 O Hartaigh B, Berman DS, et al. Current trends in patients with chronic total occlusions undergoing coronary CT angiography. Heart. 2015;101:1212–1218.

18. Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol. 2001;38:409–414.

19. Mehran R, Claessen BE, Godino C, et al. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. JACC Cardiovasc Interv. 2011;4:952–961.

20. Melchior JP, Doriot PA, Chatelain P, et al. Improvement of left ventricular contraction and relaxation synchronism after recanalization of chronic total coronary occlusion by angioplasty. J Am Coll Cardiol. 1987;9:763–768.

21. Godino C, Bassanelli G, Economou F, et al. Predictors of cardiac death in patients with chronic coronary total occlusion not revascularized by PCI. Int J Cardiol. 2013;168:1402–1409.

22. Arslan U, Balcioglu AS, Timurkaynak T, Cengel A. The clinical outcomes of percutaneous coronary intervention in chronic total coronary occlusion. Int Heart J. 2006;47:811–819.

23. George S, Cockburn J, Clayton TC, et al. British cardiovascular intervention society; national institute for cardiovascular outcomes research. Long-term follow-up of elective chronic total coronary occlusion angioplasty - analysis from the U.K. Central cardiac audit database. J Am Coll Cardiol. 2014;64:235–243.

24. Goel PK, Khanna R, Pandey CM, Ashfaq F. Long-term outcomes post chronic total occlusion intervention-implications of completeness of revascularization. J Intervent Cardiol. 2018 Jun;31(3):293–301.

25. Dash D. A step by step guide to mastering retrograde coronary chronic total occlusion intervention in 2018: the author’s perspective. Indian Heart J. 2018 Dec;70(suppl 3):S446–S455. https://doi.org/10.1016/j.ihj.2018.08.011.

26. Prasad A, Rihal C, Lennon R, Wiste H, Singh M, Holmes D. Trends in outcomes after percutaneous coronary intervention for chronic total occlusion: a 25-year experience from the Mayo clinic. J Am Coll Cardiol. 2007;49:1611–1618.

27. Lee SW, Lee JY, Park DW, et al. Long-term clinical outcomes of unsuccessful revascularization with drug-eluting stents of true chronic total occlusion. Cathet Cardiovasc Interv. 2011;78:346–353.

28. Hoye A, van Domburg RT, Sonnenschein K, Serruys PW. Percutaneous coronary intervention for chronic total occlusions: the Thorax center experience 1992-2002. Eur Heart J. 2005;26:2630–2636.

29. Galassi AR, Tomasellos SD, Reifart N, et al. In-hospital out-comes of percutaneous coronary intervention in patients with chronic total occlusion: insights from the ERCTO (European Registry of Chronic Total Occlusion) registry. Eurointervention. 2011;7:472–479.

30. Rathore S, Matsuo H, Terashima M, et al. Procedural and in-hospital outcomes after percutaneous coronary intervention for chronic total occlusions of coronary arteries 2002 to 2008. JACC Cardiovasc Interv. 2009;2:489–497.

31. Yoyal D, Aflalo J, Rinfret S. Effectiveness of recanalisation of chronic total occlusions: a systematic review and meta-analysis. Am Heart J. 2010;160:179–187.

32. Naganuma T, Tsujita K, Mitomo S, et al. Impact of chronic kidney disease on outcomes after percutaneous coronary intervention for chronic total occlusions (from the Japanese multicenter registry). Am J Cardiol. 2018 Jun 15;121(12):1519–1523. https://doi.org/10.1016/j.amjcard.2018.02.032.

33. Saito S. Progress in angioplasty for chronic total occlusions again. Cathet Cardiovasc Interv. 2010;76:850–851.

34. Godino C, Sharp AS, Carlino M, Colombo A. Crossing CTOs: the tips, tricks, and specialist kit that can mean the difference between success and failure. Cathet Cardiovasc Interv. 2009;74:1019–1046.